guest ::
| Home > Publications database > The gut microbiome in intravenous immunoglobulin‐treated chronic inflammatory demyelinating polyneuropathy > print |
| Home > Publications database > The gut microbiome in intravenous immunoglobulin‐treated chronic inflammatory demyelinating polyneuropathy > print |
| 001 | 1005757 | ||
| 005 | 20240213111724.0 | ||
| 024 | 7 | _ | |a 10.1111/ene.15679 |2 doi |
| 024 | 7 | _ | |a 1351-5101 |2 ISSN |
| 024 | 7 | _ | |a 1468-1331 |2 ISSN |
| 024 | 7 | _ | |a 10.34734/FZJ-2023-01611 |2 datacite_doi |
| 024 | 7 | _ | |a 36651357 |2 pmid |
| 024 | 7 | _ | |a WOS:000925036100001 |2 WOS |
| 037 | _ | _ | |a FZJ-2023-01611 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Svačina, Martin K. R. |0 0000-0001-8166-5132 |b 0 |
| 245 | _ | _ | |a The gut microbiome in intravenous immunoglobulin‐treated chronic inflammatory demyelinating polyneuropathy |
| 260 | _ | _ | |a Oxford [u.a.] |c 2023 |b Wiley-Blackwell |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1705499826_10185 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a AbstractBackground and purpose: The gut microbiome is involved in autoimmunity. Data on its composition in chronic inflammatory demyelinating polyneuropathy (CIDP), the most common chronic autoimmune disorder of peripheral nerves, are currently lacking.Methods: In this monocentric exploratory pilot study, stool samples were prospectively collected from 16 CIDP patients (mean age 58 ± 10 years, 25% female) before and 1 week after administration of intravenous immunoglobulin (IVIg). Gut microbiota were analyzed via bacterial 16S rRNA gene sequencing and compared to 15 age-matched healthy subjects (mean age 59 ± 15 years, 66% female).Results: The gut microbiota of CIDP patients showed an increased alpha-diversity (p = 0.005) and enrichment of Firmicutes, such as Blautia (p = 0.0004), Eubacterium hallii (p = 0.0004), or Ruminococcus torques (p = 0.03), and of Actinobacteriota (p = 0.03) compared to healthy subjects. IVIg administration did not alter the gut microbiome composition in CIDP in this short-term observation (p = 0.95).Conclusions: The gut microbiome in IVIg-treated CIDP shows distinct features, with increased bacterial diversity and enrichment of short-chain fatty acid producing Firmicutes. IVIg had no short-term impact on the gut microbiome in CIDP patients. As the main limitation of this exploratory pilot study was small cohort size, future studies also including therapy-naïve patients are warranted to verify our findings and to explore the impact of long-term IVIg treatment on the gut microbiome in CIDP.Keywords: autoimmunity; firmicutes; immune neuropathies; intestinal barrier; short-chain fatty acids (SCFA). |
| 536 | _ | _ | |a 5251 - Multilevel Brain Organization and Variability (POF4-525) |0 G:(DE-HGF)POF4-5251 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Sprenger-Svačina, Alina |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Tsakmaklis, Anastasia |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Rüb, Alina M. |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Klein, Ines |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Wüstenberg, Hauke |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Fink, Gereon R. |0 P:(DE-Juel1)131720 |b 6 |u fzj |
| 700 | 1 | _ | |a Lehmann, Helmar C. |0 0000-0001-6205-2293 |b 7 |e Corresponding author |
| 700 | 1 | _ | |a Vehreschild, Maria J. G. T. |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Farowski, Fedja |0 P:(DE-HGF)0 |b 9 |
| 773 | _ | _ | |a 10.1111/ene.15679 |g p. ene.15679 |0 PERI:(DE-600)2020241-6 |n 11 |p 3551-3556 |t European journal of neurology |v 30 |y 2023 |x 1351-5101 |
| 856 | 4 | _ | |y OpenAccess |u https://juser.fz-juelich.de/record/1005757/files/PDF.pdf |
| 856 | 4 | _ | |y OpenAccess |x icon |u https://juser.fz-juelich.de/record/1005757/files/PDF.gif?subformat=icon |
| 856 | 4 | _ | |y OpenAccess |x icon-1440 |u https://juser.fz-juelich.de/record/1005757/files/PDF.jpg?subformat=icon-1440 |
| 856 | 4 | _ | |y OpenAccess |x icon-180 |u https://juser.fz-juelich.de/record/1005757/files/PDF.jpg?subformat=icon-180 |
| 856 | 4 | _ | |y OpenAccess |x icon-640 |u https://juser.fz-juelich.de/record/1005757/files/PDF.jpg?subformat=icon-640 |
| 909 | C | O | |o oai:juser.fz-juelich.de:1005757 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 6 |6 P:(DE-Juel1)131720 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5251 |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-22 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0 |0 LIC:(DE-HGF)CCBYNCND4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J NEUROL : 2022 |d 2023-10-22 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2023-10-22 |w ger |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-22 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-22 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J NEUROL : 2022 |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-22 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|